Literature DB >> 10784631

Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.

R C Zellars1, S G Hilsenbeck, G M Clark, D C Allred, T S Herman, G C Chamness, R M Elledge.   

Abstract

PURPOSE: The loss of p53 function is a recognized adverse prognostic factor in invasive breast cancer. Several studies have shown a relationship between the nuclear accumulation of p53 protein (a surrogate marker of p53 inactivation) and poor disease-free and overall survival. In general, however, these studies did not report the prognostic value of p53 for local failure, which we have therefore assessed retrospectively here.
MATERIALS AND METHODS: Accumulation of p53 protein was evaluated by immunohistochemistry in 1,530 mastectomy-treated breast cancer patients (259 radiation therapy [RT]- and 1,271 mastectomy only [No RT]-treated patients). Statistical comparisons were made between p53 protein accumulation, estrogen/progesterone receptors, nodal status, tumor size, and local failure rate (LFR). Local failure was defined as tumor recurrence involving the chest wall and/or the ipsilateral supraclavicular/axillary lymph nodes. The median follow-up period was 62 months.
RESULTS: In the No RT group, the LFR was 9.1% and 16. 5% in p53-negative and p53-positive patients, respectively (P<.001). Multivariate analysis revealed that p53 protein accumulation was significantly associated with an increased risk of local relapse (relative risk [RR], 1.7; 95% confidence interval [CI], 1.2 to 2.4). Nodal status and tumor size were also significant factors. In the RT group, the LFR was 9.3% and 21.5% in p53-negative and p53-positive patients, respectively (P = .009). Multivariate analysis revealed that p53 protein accumulation was significantly associated with an increased risk of local relapse (RR, 2.5; 95% CI, 1.1 to 5.7), as was nodal status.
CONCLUSION: Nuclear accumulation of p53 protein is independently associated with a significantly increased local failure rate in breast cancer patients treated with mastectomy, with or without radiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10784631     DOI: 10.1200/JCO.2000.18.9.1906

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.

Authors:  Hye Ryoung Koo; Jeong Seon Park; Keon Wook Kang; Wonshik Han; In Ae Park; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

2.  Breast-conserving therapy and modified radical mastectomy for primary breast carcinoma: a matched comparative study.

Authors:  Lize Wang; Tao Ouyang; Tianfeng Wang; Yuntao Xie; Zhaoqing Fan; Benyao Lin; Jinfeng Li
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

3.  An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.

Authors:  Jing Zhang; Yahong Wang; Quangui Yin; Wei Zhang; Tongxian Zhang; Yun Niu
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

4.  P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.

Authors:  Lun-Xiu Qin; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Xin-Da Zhou; Qing-Hai Ye; Yuan Ji; Li-Wen Huang; Hu-Liang Jia; Hui-Chuan Sun; Lu Wang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

5.  A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers.

Authors:  Natalya Frolova; Mick D Edmonds; Thomas M Bodenstine; Robert Seitz; Martin R Johnson; Rui Feng; Danny R Welch; Andra R Frost
Journal:  Tumour Biol       Date:  2009-07-16

6.  Prognosis for Survival of Young Women with Breast Cancer by Quantitative p53 Immunohistochemistry.

Authors:  David E Axelrod; Kinsuk Shah; Qifeng Yang; Bruce G Haffty
Journal:  Cancer Clin Oncol       Date:  2012

Review 7.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

8.  Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.

Authors:  Wainer Zoli; Paola Ulivi; Anna Tesei; Francesco Fabbri; Marco Rosetti; Roberta Maltoni; Donata Casadei Giunchi; Luca Ricotti; Giovanni Brigliadori; Ivan Vannini; Dino Amadori
Journal:  Breast Cancer Res       Date:  2005-06-22       Impact factor: 6.466

9.  Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?

Authors:  M I Koukourakis; A Giatromanolaki; G Galazios; E Sivridis
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

10.  Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients.

Authors:  J A van der Hage; L J C M van den Broek; C Legrand; P C Clahsen; C J A Bosch; E C Robanus-Maandag; C J H van de Velde; M J van de Vijver
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.